JOSÉ LUIS
REVUELTA HERRERO
Profesor asociado
Hospital General Universitario Gregorio Marañón
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Hospital General Universitario Gregorio Marañón (12)
2024
-
Patient-reported outcome measures in severe asthma: an expert consensus
Journal of Asthma, Vol. 61, Núm. 6, pp. 619-631
-
Prevalence of potentially inappropriate medications and prescription dynamics in elderly hospitalized patients in Spain
BMC Geriatrics, Vol. 24, Núm. 1
2023
-
Complementary and alternative medicine in cancer patients: characteristics of use and interactions with antineoplastic agents
Journal of Cancer Research and Clinical Oncology, Vol. 149, Núm. 7, pp. 2855-2882
-
Medication guide for dose adjustment and management of cardiotoxicity and lipid metabolic adverse events of oral antineoplastic therapy
Frontiers in Oncology, Vol. 13
2022
-
A New Methodology to Estimate Drug Cost Avoidance in Clinical Trials: Development and Application
Frontiers in Oncology, Vol. 12
-
A smartphone app to improve the safety of patients undergoing treatment with oral antineoplastic agents: 4 years of experience in a university hospital
Frontiers in Public Health, Vol. 10
-
Implantación de una metodología para evaluar patient‑reported outcomes en pacientes con cáncer de pulmón: Protocolo del estudio PeOpLe (Patient‑reported Outcomes in Lung cancer )
Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, Vol. 46, Núm. 4, pp. 265-269
-
Medication guide for the perioperative management of oral antineoplastic agents in cancer patients
Expert Opinion on Drug Safety, Vol. 21, Núm. 1, pp. 107-119
-
Smartphone-Based Ecological Momentary Assessment for the Measurement of the Performance Status and Health-Related Quality of Life in Cancer Patients Under Systemic Anticancer Therapies: Development and Acceptability of a Mobile App
Frontiers in Oncology, Vol. 12
2021
-
Assessment of diarrhea as side effect of oral targeted antineoplastic agents in clinical practice
Supportive Care in Cancer, Vol. 29, Núm. 8, pp. 4673-4681
-
Clinical course of severe patients with COVID-19 treated with tocilizumab: report from a cohort study in Spain
Expert Review of Clinical Pharmacology, Vol. 14, Núm. 2, pp. 249-260
2020
-
Risks and medication errors analysis to evaluate the impact of a chemotherapy compounding workflow management system on cancer patients’ safety
Health Informatics Journal, Vol. 26, Núm. 3, pp. 1995-2010